NVDL: Final Liquidating Payment ($0.01/share); Payable upon surrender of certificates.

FINRA deleted symbol:

http://otce.finra.org/DLDeletions

NEWS! http://www.businesswire.com/news/home/20160204006466/en/
What does this mean for us: being patient for the next months?

Good question. Consolidating a bit IMO

Well, what seems to be going on here... huh?

Sold my 1,000,000 Shares of NVDL this week. Got about $0.007 per share. Made a few hundreds bucks and was happy to move on.

Who knows what the Rat has in store for the $2M in cash the company has. Maybe he will offer shareholders another buyout at 1 cent per share. My guess is that he owns most of the shares by now.

Wanted to put money into something that had a chance of making money.

The best thing that NVDL did was introduce me to SUDA. I think SUDA has a chance for strong profits in a few years.

GLTA!

I cannot add anything to this. My guess is that he is not stupid and would not do somehting that could land him in jail.

The rumour is that he "took" them for his own purposes ?

Can anyone confirm ?

The Rat (CEO) supposedly sold them to pay bills. Most feel he has been paying himself a big salary since driving the company into the ground.

I have never seen one good word said about him.

Could someone pls explain just who infact receieved the Suda options and at what price ?

HubInvestor,

Thanks.

Hate to hear that they have sold off the stock and options in SUDA.

Looks like this is going to come to closure soon.

While I hate the price of 1 cent, I will be ahead a little an hopefully not take a loss.

news:

http://www.marketwatch.com/story/novadel-announces-proposed-actions-to-complete-liquidation-of-assets-and-cash-distribution-to-shareholders-2014-03-26?reflink=MW_news_stmp

I believe anyone could come in and buy the shell. I'll just hang onto the few shares I still have and see what happens. Doesn't make sense to sell shares lower than .01 if that's the final price out the door.

NP

IT is a non reporting shell. So I think it has less value than a reporting shell.

Not sure on the value of the shell.

with the news, you get .01 per share, but then you're shares will be in a company that does nothing? is this a shell which could be sold?

This is a very slow board.

Has anyone been in touch with MR Ratoff lately to see where this company is going?

Their SUDA options (10M @ 5 cents each) expire on 31 Dec 2015. He will need to take action before then to lock in the profit. The options are "in the money" at this time. Suda closed 14 Mar 2014 at $0.061 USD.

Thanks. While this is probably the reason, it really does not make any sense to me.

I asked the same question. I think it has something to do with the stock they hold in Suda.

JRT,

Any idea why the NVDL board was renamed to SUDA LTD (NVDL)?

As we both know these are two completely different companies.

Appreciate what you can provide.

SUDA LTD PUBLISHES QUARTERLY NEWSLETTER on 17 Feb 2014

Available at the following link:

http://member.afraccess.com/media?id=CMN://6A667751&filename=20140217/SUD_01491812.pdf

Here's the real story -

NovaDel Announces Completion of the Sale of Substantially All Assets to Suda Ltd.

NovaDel Pharma Inc. August 13, 2013 4:01 PM

BRIDGEWATER, N.J.--(BUSINESS WIRE)--

NovaDel Pharma Inc. (“NovaDel” or “the Company”) (OTC Pink: NVDL) announced today the completion of the sale of substantially all of the Company’s assets to Suda Ltd. (the “Suda Transaction”).

As previously disclosed, the Suda Transaction includes the sale of NovaDel’s patents and trademarks relating to its NovaMist technology. The Suda Transaction, as contemplated, does not include the NitroMist® or ZolpiMist™ intellectual property or licenses. NovaDel received $400,000 in cash, 50,000,000 shares of Suda common stock and 10,000,000 options for the purchase of Suda common shares at a purchase price of $0.05 per share. It is the Company’s intention to use part of the proceeds from the Suda Transaction, after transaction expenses, to reduce its outstanding liabilities.

ABOUT NOVADEL PHARMA

NovaDel Pharma Inc. is a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products. The Company’s patented oral spray drug delivery technology seeks to improve the efficacy, safety, patient compliance, and patient convenience for a broad range of prescription pharmaceuticals. NovaDel has two marketed products that have been approved by the FDA: NitroMist® for the treatment of angina, and ZolpiMist™ for the treatment of insomnia. To find out more about NovaDel Pharma Inc. (OTC Pink: NVDL), visit our website at www.novadel.com.

FORWARD-LOOKING STATEMENTS:

Except for historical information contained herein, this document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the Company’s ability to obtain additional required financing or achieve other strategic alternatives (the lack of which would cause the Company to file for bankruptcy), the ability of third parties to successfully commercialize the Company’s products, the successful completion of its clinical trials, including pilot pharmacokinetic feasibility studies, the successful completion of its preclinical studies, the ability to develop products (independently and through collaborative arrangements), the ability to commercialize and obtain FDA and other regulatory approvals for products under development, and the acceptance in the marketplace for oral spray products. The Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company’s control.

In addition, our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any of our products could materially impact the Company's actual results. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2011 filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Contact:
NovaDel Pharma Inc.
Steven B. Ratoff, 520-245-6905

SUDA

Suda did not acquire Novadel. Suda acquired most of the IP of Novadel. Novadel still trades on the OTC under NVDL. NVDL owns 50M shares of SUDA and an option to buy 10M more shares at 5 cents each. (see note below from CEO that puts these 50M shares in question)

Novadel also still owns the IP rights to Zopolmist.

Here is my email from the NVDL CEO:

I sent Mr Ratoff the note below and his reply is below my note.

On Feb 4, 2014, at 3:15 PM, SChris wrote:

Mr Ratoff,

Greetings!

I am an investor in Novadel with 1 million shares to my name.

I realize that you sold off most of the assets but just want to know what the next steps are?

At what point will the assets of the company be passed on to the investors?

I am anxious to get my share of the SUDA stock that Novadel owns.

I appreciate what you can tell me.

"LinkedIn INMAIL: ACCEPTED

Steven Ratoff has accepted your request.

Title: Novadel Pharma

The assets that remain are-

-The zolpimist license and intellectual property offset by what is owed to the FDA

-SUDA stock not sold to pay creditors.

Shareholder approval is required to liquidate. It is not yet clear whether distributing shares of SUDA or proceeds from sale of SUDA shares is the preferable route to liquidate.

Timing is an issue as the remaining non SUDA assets have to be sold and all liabilities settled.

Press releases will be issued when these assets are sold and future plans are announced.

Steven Ratoff


Sent from my iPhone"

This email from him raises some questions:

1. How many shares of SUDA has been sold from the 50M?

2. When will we see any press releases?

Suda Ltd, formerly Eastland Medical Systems Ltd, is engaged in pharmaceutical development and medical devices and consumables distribution. The Company operates in two segments: Eastland Medical Systems (Eastland) and Westcoast Surgical & Medical Supplies (Westcoast). Eastland Medical Systems is the pharmaceutical development segment and performs research and development to create new human pharmaceutical products by combining proven drugs with delivery technologies. Eastland Medical (WA) Pty Ltd trading as Westcoast Surgical & Medical Supplies is a sales and logistic operation for medical devices and consumables. The Company is in the process of commercializing a sub-lingual (under the tongue spray) anti-malarial delivery system ArTiMist for the treatment of complicated falciparum malaria in children. In August 2013, the Company acquired NovaDel Pharma Inc

Does anyone know if there was a "lockout period" on the sale of the 50M Shares that NVDL received from SUDA? This would preclude NVDL from selling these shares for a period of time.

The option on the 10M shares at 5 cents each expires on 31 Dec 2015.

Here is a link to the info:

http://www.sudaltd.com.au/attachments/article/28/638%20NovaDel%20shareholders%20approve%20Suda%20Acquisition%2023%20july.pdf


Acquisition Price

The acquisition price of the NovaDel Intellectual Property
is broken into 3 components:

1. Cash US $400,000

2. Shares 50,000,000 shares to be issued on closing

3. Options 10,000,000 unlisted options to be issued on closing with exercise price at 5 cents, expiry date 31 December 2015.

This same report was advertised at Yahoo for $138.00.

Here (see below) you can get it for 10 British Pounds.

(A Link to SUDA's Annual Reports for Free is at the bottom of this message)

Analyst Research Report Snapshot
title:

Suda Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
price:

£10.00
provider:

Reuters Investment Profile
date:

08 Feb 2014
pages:

12
type:

AcrobatPDF
companies referenced:

SUD.AX
Available for Immediate Download
summary:

This report is essential reading for any serious investor, providing comprehensive financial information on a company's performance, position and cash flows over the past 3 years, including interim data. This information, extracted from reported financial statements, forms the building blocks for any analysis undertaken by investment professionals. - Key Stats and Ratios including; Valuation Ratios (e.g. Price/Earnings), Per Share Data (e.g. EPS), Profitability Ratios (e.g. Gross Margin), Management Effectiveness (e.g. Return on Equity), Financial Strength (e.g. Quick Ratio) and Dividend Information (e.g. Dividend Yield). - 3 years of history are available for most ratios (see above). - Share performance data and 12 month chart - Profit & Loss Account (3 years) - Balance sheet (3 years) - Cash Flow Statement (3 years) - Educational content: Definitions of ratios and guidance on using the data - Graphical analysis: All the key data in the report is charted. Reuters Investment Profile reports are now available for over 25,000 companies globally.Every report is updated weekly to ensure that the information remains current.

Link to SUDA's Annual Reports for Free:

http://www.sudaltd.com.au/index.php/annual-reports

Thanks for sharing. Looking at the SUDA stock price on the AUS exchange - they were around .03 per share until November, climbed above .08, now resting at around .06 PPS.
http://www.asx.com.au/asx/research/companyInfo.do?by=asxCode&asxCode=SUD

Let's be overly optimistic and say they sold all of those 50 million shares at the .08 peak. That's $4 million. According to the 2012 Financials we had liabilities of $4.3 million, including money owed to the FDA. So that 50 million shares of SUDA in all likelihood is almost all gone. I just don't see much coming from that. Really sucks because the technology had value.

All IMO,

NP

I agree with the accumulation. I am not sure there is any incentive for the company management to move quickly on this. The longer they wait the more investors will become frustrated and eventually sell their positions. I believe this is exactly what management wants to happen.

At this point, we the investors are in the dark and management clearly has the upper hand. Management is the only one who knows what the true value of the company is at this point. All we can do is speculate based upon what we feel is correct.

I am not sure as a non reporting company what management's responsibility to the current shareholders is.

Thanks, good to know. It was my opinion that insiders have been slowly accumulating shares. I think they have slowed down to keep the PPS down.

I sent Mr Ratoff the note below and his reply is below my note.

On Feb 4, 2014, at 3:15 PM, SChris wrote:

Mr Ratoff,

Greetings!

I am an investor in Novadel with 1 million shares to my name.

I realize that you sold off most of the assets but just want to know what the next steps are?

At what point will the assets of the company be passed on to the investors?

I am anxious to get my share of the SUDA stock that Novadel owns.

I appreciate what you can tell me.

"LinkedIn INMAIL: ACCEPTED

Steven Ratoff has accepted your request.

Title: Novadel Pharma

The assets that remain are-

-The zolpimist license and intellectual property offset by what is owed to the FDA

-SUDA stock not sold to pay creditors.

Shareholder approval is required to liquidate. It is not yet clear whether distributing shares of SUDA or proceeds from sale of SUDA shares is the preferable route to liquidate.

Timing is an issue as the remaining non SUDA assets have to be sold and all liabilities settled.

Press releases will be issued when these assets are sold and future plans are announced.

Steven Ratoff


Sent from my iPhone"

This email from him raises some questions:

1. How many shares of SUDA has been sold from the 50M?

2. When will we see any press releases?

Why did IHUB change the name of the Novadel Board to SUDA LTD?

Does anyone have a good explantion?

95% of Novadel's assets is their stock in SUDA LTD.

I find this odd!

I guess so. Ihub just changed the board name today

Referring to this?
http://ih.advfn.com/p.php?pid=nmona&article=58800804

Nupapa

Name change ????

LOOKING TO DEVLEOPM A POSITION

BEST PENNY'S OF 2014

http://www.beststocks2016.com/best-penny-stocks-to-buy-for-2014.html

GREAT POTENTIAL HERE

how is this stock looking?

Go NVDL!!! MY chart tells me tomorrow will go green. I just put in today late bloomer. REady to uptrend. INsider putting in to keep this stock moving

Very low volume today. Suda is up too. All considered, this is a pretty good hold stock.

Hold out for our piece of the pie once this company gets chopped up and distributed to the shareholders.

Every share of NVDL is worth 0.444 shares of SUDA. This means that for every 100 shares of NVDL that you own you control 44.4 shares of SUDA.

Think about this. The current value of 100 shares of NVDL is $0.90 (90 cents). The value of 44.4 shares of SUDA is $3.41.

For 90 cents invested in NVDL you control $3.41 of SUDA.

If and when NVDL divides up the assets to shareholders we should all make out well.

The smart people are accumulating this over time and letting the not so smart ones give up their shares at a major discount to their real value.

Of course this is all my opinion and you should not invest based upon the opinion of one person - do your own DD!

I think it is insiders also. I see steady action on no news. They don't want any volume either. Nothing to set off triggers.

How do you know there is steady insider buying?

While I hope there is, I am not aware of how to tell with this non reporting stock.

Totally agree long term hold should bring a new 52 high of.035 playing catch up with suda.

Steady insider share buying is a great sign...great things ahead

Current Assets of NovaDel

Does anyone have a list of what assets that NovaDel still retains?

From reading old posts on Yahoo I have seen remarks that they still own the following:

1. Rights to Artimist
2. Rights to Zolpimist
3. Rights to SUD-001

Are these correct?

Are there other assets that someone knows about?

The next question will be known liabilities.

Great post this seems to me to be 1 of the few future gold mines,im holding still,i baught most of my shares at an average of 0060 plus i like that it dosnt always have the near same daily volume indicating to me to be attracting new people.

NVDL's real value is 3.2 cents a share.

This is based solely upon the current value of SUDA Stock.

Here is the math:

Value of NVDL based upon them controlling 60,000,000 shares of SUDA

X = Suda Stock Price.-...$0.08


Value of 50 Million Shares of SUDA = 50M * X

50,000,000......*.........0.08 cents....................$4,000,000

Options for 10 M Shares of SUDA = (10M * (X - 0.05))

10,000,000......*.........0.03 cents......................$300,000

..........................................................Total...$4,300,000

................Number of Outstanding NVDL Shares......134,890,000

Actual Value of NVDL $4,300,000 / 134,890,000 = .........$0.032

Using this model when SUDA is at $2.26 per share the value of NVDL is $1.00 per share.

If you want an emailed copy of the model (Excel) please send me a private message with your email in it.

Great Day! Up 46%. Let's see what tomorrow brings!

trying to make a push here...see what happens

Looks like going to the old 52 week high im holding for .05 still moving alot and thin the way i like it.

Somebody wanted this very badly and they were willing to pay for it.

Cannot wait to hear what is going on.

I am waiting for $1.00 a share before I even think about selling.

I am willing to wait for SUDA to take this to $1.00.